SANTA MONICA, Calif. , March 07, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report fourth quarter 2021 financial results and pipeline updates

SANTA MONICA, Calif. , Feb. 10, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced positive topline results from a multi-dose pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, an investigational treatment for opioid overdose.

SANTA MONICA, Calif. , Jan. 24, 2022 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced a modification to its contract with the Biomedical Advanced Research and Development Authority (“BARDA”) for an additional commitment of up to $2.2 million to support

Phase 2 trial to evaluate reduction in heavy drinking as measured by a change in the World Health Organization drinking risk levels 1 Trial is informed by results from Phase 1 studies that showed pharmacokinetic properties of OPNT002 well suited for ‘as needed’ administration, either in